MedTrace Logo

Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19

NCT04594343 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2021-10-08

No results posted yet for this study

Summary

This clinical trial evaluates the safety, efficacy, and biomarker levels of FDA-approved drug disulfiram in the treatment of adult subjects hospitalized with moderate COVID-19. Disulfiram may limit the hyperinflammatory response associated with COVID-19 and reduce the risk of progression to severe illness.

Subjects will be screened and randomized to receive either daily administration of oral disulfiram or placebo for 14 days. Subjects will be followed up on Day 28.

Conditions

  • Covid19

Interventions

DRUG

Disulfiram

The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days

DRUG

Placebo

The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days

Sponsors & Collaborators

  • Spring Research Foundation

    collaborator NETWORK

  • ETICA

    lead OTHER

Principal Investigators

  • Augusto Mota, MD/PhD · ETICA

  • Wendy Cousin, PhD · Spring Research Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2021-09-10
Completion
2021-09-25

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04594343 on ClinicalTrials.gov